The mitogen-activated protein kinase (MAPK) pathway is constitutively activated in approximately 90% of all melanomas [3], and new drugs targeting this pathway, e.g inhibitors of mutated BRAF or MEK, initially showed promising effects in vitro. Here, BRAF is linked to melanoma.